Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR)
11.08
+0.23 (2.12%)
NASDAQ· Last Trade: Aug 7th, 9:46 AM EDT
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · August 6, 2026
Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · August 6, 2026
The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · August 5, 2026
A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst consensus of roughly $419 million for the full year. If you lost money on PHAR, click here to submit your losses for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky · Via Business Wire · August 4, 2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · March 3, 2026
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · February 24, 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · February 17, 2026
